Spark Therapeutics (NASDAQ:ONCE) was downgraded by stock analysts at Leerink Swann from an “outperform” rating to a “market perform” rating in a report issued on Tuesday. They currently have a $49.00 target price on the biotechnology company’s stock. Leerink Swann’s target price would indicate a potential upside of 6.73% from the company’s previous close. Leerink Swann also issued estimates for Spark Therapeutics’ Q1 2018 earnings at ($1.75) EPS, Q2 2018 earnings at ($1.47) EPS, Q3 2018 earnings at ($1.21) EPS, FY2019 earnings at ($2.90) EPS and FY2020 earnings at ($2.57) EPS.

Other equities research analysts have also issued reports about the company. Evercore ISI began coverage on Spark Therapeutics in a research report on Wednesday, August 16th. They set an “in-line” rating and a $83.00 price target on the stock. Cantor Fitzgerald reissued a “buy” rating on shares of Spark Therapeutics in a research report on Friday, August 25th. UBS lowered Spark Therapeutics from a “buy” rating to a “neutral” rating and dropped their price target for the company from $92.00 to $51.00 in a research report on Tuesday. BMO Capital Markets set a $89.00 price target on Spark Therapeutics and gave the company a “buy” rating in a research report on Tuesday, October 10th. Finally, Barclays began coverage on Spark Therapeutics in a research report on Wednesday, September 6th. They set an “overweight” rating and a $104.00 price target on the stock. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating and fifteen have assigned a buy rating to the company’s stock. Spark Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $76.19.

Shares of Spark Therapeutics (ONCE) opened at $45.91 on Tuesday. Spark Therapeutics has a 52-week low of $41.06 and a 52-week high of $91.75.

Spark Therapeutics (NASDAQ:ONCE) last posted its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($1.90) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.79) by ($0.11). The firm had revenue of $1.90 million for the quarter, compared to analyst estimates of $1.40 million. Spark Therapeutics had a negative net margin of 1,090.11% and a negative return on equity of 60.01%. The business’s revenue was up 45.8% on a year-over-year basis. During the same period in the prior year, the company posted ($1.07) earnings per share. sell-side analysts forecast that Spark Therapeutics will post -7.6 EPS for the current year.

In other Spark Therapeutics news, CEO Jeffrey D. Marrazzo sold 20,000 shares of the stock in a transaction on Monday, November 13th. The stock was sold at an average price of $71.54, for a total value of $1,430,800.00. Following the sale, the chief executive officer now directly owns 250,000 shares of the company’s stock, valued at $17,885,000. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Daniel Faga sold 1,500 shares of the firm’s stock in a transaction on Tuesday, September 19th. The shares were sold at an average price of $85.00, for a total value of $127,500.00. Following the transaction, the insider now directly owns 1,500 shares in the company, valued at $127,500. The disclosure for this sale can be found here. Insiders sold 1,068,809 shares of company stock worth $89,809,385 over the last ninety days. 7.30% of the stock is owned by corporate insiders.

Several institutional investors and hedge funds have recently modified their holdings of ONCE. Janus Henderson Group PLC acquired a new position in shares of Spark Therapeutics during the second quarter valued at $30,848,000. Orbimed Advisors LLC acquired a new position in shares of Spark Therapeutics during the third quarter valued at $38,340,000. Jennison Associates LLC acquired a new position in shares of Spark Therapeutics during the third quarter valued at $27,239,000. JPMorgan Chase & Co. increased its holdings in shares of Spark Therapeutics by 15.0% during the third quarter. JPMorgan Chase & Co. now owns 1,848,988 shares of the biotechnology company’s stock valued at $164,986,000 after purchasing an additional 241,016 shares during the period. Finally, BlackRock Inc. increased its holdings in shares of Spark Therapeutics by 11.6% during the second quarter. BlackRock Inc. now owns 2,053,734 shares of the biotechnology company’s stock valued at $122,689,000 after purchasing an additional 213,520 shares during the period. 94.94% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “Leerink Swann Downgrades Spark Therapeutics (ONCE) to Market Perform” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The original version of this piece can be read at https://www.thecerbatgem.com/2017/12/14/leerink-swann-downgrades-spark-therapeutics-once-to-market-perform.html.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Analyst Recommendations for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Stock Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related stocks with our FREE daily email newsletter.